Luciana dos Santos Domingues
Research Subjects
Luciana dos Santos Domingues has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ana Carolina Ribeiro Correa
Universidade Federal de São Paulo – Department of Pediatric Oncology and Bone Marrow Transplant – Pediatric Oncology Institute – São Paulo (SP), Brazil
3 shared publications - Paulo Klinger
Hospital Santa Marcelina – Associação para Criança e Adolescente com Câncer – São Paulo (SP), Brazil
3 shared publications - Adriana Seber
Hospital Samaritano Higienópolis – São Paulo (SP), Brazil
2 shared publications - Antonella Zanette
Hospital Erastinho – Curitiba (PR), Brazil
2 shared publications - Antonio Vaz de Macedo
Hospital da Polícia Militar – Belo Horizonte (MG), Brazil
2 shared publications - Carla Nolasco Monteiro Breviglieri
Hospital Samaritano de São Paulo – São Paulo (SP), Brazil
2 shared publications
Latest Publications
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia
This article details the 2025 consensus update from the Brazilian Group for Pediatric Bone Marrow Transplantation and the Brazilian Society for Pediatric Oncology regarding hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL). Allogeneic HSCT is the standard treatment for high-risk or relapsed ALL. Key indications include, in first remission, very high risk patients defined by primary induction failure or positive minimal residual disease (MRD) after consolidation. In second remission, it is indicated for early bone marrow relapse, early isolated extramedullary B-cell relapse, and all T-cell ALL relapses. The consensus recommends myeloablative conditioning as standard, preferring total body irradiation based regimens for children over 2–3 years old. The preferred donor hierarchy is a matched sibling, followed by a matched unrelated donor, with bone marrow being the preferred cell source. Post-HSCT monitoring of MRD is critical for guiding interventions and identifying relapse. This document serves as an essential, updated guide for clinical decision-making in this field.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessHematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia
This article details the 2025 consensus update from the Brazilian Group for Pediatric Bone Marrow Transplantation and the Brazilian Society for Pediatric Oncology regarding hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL). Allogeneic HSCT is the standard treatment for high-risk or relapsed ALL. Key indications include, in first remission, very high risk patients defined by primary induction failure or positive minimal residual disease (MRD) after consolidation. In second remission, it is indicated for early bone marrow relapse, early isolated extramedullary B-cell relapse, and all T-cell ALL relapses. The consensus recommends myeloablative conditioning as standard, preferring total body irradiation based regimens for children over 2–3 years old. The preferred donor hierarchy is a matched sibling, followed by a matched unrelated donor, with bone marrow being the preferred cell source. Post-HSCT monitoring of MRD is critical for guiding interventions and identifying relapse. This document serves as an essential, updated guide for clinical decision-making in this field.
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Hematopoietic cell transplantationin pediatric chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder primarily linked to the BCR-ABL fusion gene, resulting from the Philadelphia chromosome translocation. While rare in pediatric populations, CML in children presents unique biological and clinical features, often diagnosed incidentally through leukocytosis. Symptoms may include fatigue, weight loss, and splenomegaly, with advanced cases exhibiting signs of bleeding and infections. The management of pediatric CML has evolved significantly with the introduction of tyrosine kinase inhibitors (TKIs), in which imatinib remains the first-line treatment despite potential long-term toxicities. Second-generation TKIs such as dasatinib and nilotinib are alternatives for treatment resistance. Asciminib, a third-generation inhibitor, shows promise for cases resistant to other TKIs, although pediatric data are still emerging. Allogeneic hematopoietic cell transplantation (HCT) is crucial for highrisk pediatric CML cases, particularly in the blastic phase or in instances of TKI resistance. The choice of conditioning regimens, whether myeloablative or reduced-intensity, is vital, with busulfan-based regimens preferred due to lower late effects. Post-transplant, the use of TKIs can be beneficial, with molecular monitoring guiding treatment decisions. Overall, individualization of therapy considering disease phase, molecular profile, and donor availability is essential for optimizing outcomes in pediatric CML management. Close follow-up strategies involving regular molecular assessments and tailored therapeutic approaches post-HCT are critical for improving patient survival rates and managing relapses.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessHematopoietic cell transplantationin pediatric chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder primarily linked to the BCR-ABL fusion gene, resulting from the Philadelphia chromosome translocation. While rare in pediatric populations, CML in children presents unique biological and clinical features, often diagnosed incidentally through leukocytosis. Symptoms may include fatigue, weight loss, and splenomegaly, with advanced cases exhibiting signs of bleeding and infections. The management of pediatric CML has evolved significantly with the introduction of tyrosine kinase inhibitors (TKIs), in which imatinib remains the first-line treatment despite potential long-term toxicities. Second-generation TKIs such as dasatinib and nilotinib are alternatives for treatment resistance. Asciminib, a third-generation inhibitor, shows promise for cases resistant to other TKIs, although pediatric data are still emerging. Allogeneic hematopoietic cell transplantation (HCT) is crucial for highrisk pediatric CML cases, particularly in the blastic phase or in instances of TKI resistance. The choice of conditioning regimens, whether myeloablative or reduced-intensity, is vital, with busulfan-based regimens preferred due to lower late effects. Post-transplant, the use of TKIs can be beneficial, with molecular monitoring guiding treatment decisions. Overall, individualization of therapy considering disease phase, molecular profile, and donor availability is essential for optimizing outcomes in pediatric CML management. Close follow-up strategies involving regular molecular assessments and tailored therapeutic approaches post-HCT are critical for improving patient survival rates and managing relapses.
- Open Access
- 8 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia
Acute myeloid leukemia (AML) accounts for 15% to 20% of pediatric acute leukemia cases. Treatment failure is influenced by both genetic risk and response to therapy1,2,3,4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. Improved survival outcomes are associated with comprehensive strategies that combine intensive chemotherapy, effective supportive care, and hematopoietic stem cell transplantation (HCT), adjusted to the relapse risk profile of each patient6-10. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML, to provide evidence-based guidance for the appropriate management of this disease. This is the 2025 update of the previously guideline.
- 8 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessHematopoietic stem cell transplantation for pediatric acute myeloid leukemia
Acute myeloid leukemia (AML) accounts for 15% to 20% of pediatric acute leukemia cases. Treatment failure is influenced by both genetic risk and response to therapy1,2,3,4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. Improved survival outcomes are associated with comprehensive strategies that combine intensive chemotherapy, effective supportive care, and hematopoietic stem cell transplantation (HCT), adjusted to the relapse risk profile of each patient6-10. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML, to provide evidence-based guidance for the appropriate management of this disease. This is the 2025 update of the previously guideline.